DGAP-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics signs joint commercialization agreement for Epi proColon(R) in North America with Polymedco

Epigenomics AG / Key word(s): Agreement

02.10.2013 00:28

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Berlin, Germany, October 01, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that it has entered into a joint commercialization agreement with
Polymedco Inc. Both companies will jointly commercialize Epi proColon(R),
Epigenomics' blood-based test for colorectal cancer (CRC) screening, in
North America.

Under the terms of the agreement, Polymedco will deploy its CRC dedicated
sales force and technical support staff, administration, logistics and
other support functions to ensure the optimum market introduction and
roll-out of Epi proColon(R) once the test is potentially approved by the US
Food and Drug Administration. Both parties will work jointly on the
marketing, launch and development strategies and with key payers to obtain
favorable reimbursement coverage. Epigenomics will retain the
responsibility to manufacture the product and to support it from the
medical and regulatory point of view, including activities necessary to
achieve inclusion in major cancer screening guidelines post approval. A
working group comprised of representatives of both companies will oversee
the launch and commercial roll-out and engage in activities necessary to
ensure the commercial success of the product once it becomes available to
the market. The companies agreed to a combined transfer price and profit
sharing agreement subject to minimum annual sales of test kits from
Epigenomics to Polymedco.

Polymedco is the largest provider of CRC screening tests in North America,
with more than USD 50m in annual sales for its cancer diagnostics products
and an established customer base of more than 1500 laboratories. The
significant know-how and commitment of Polymedco to the CRC screening space
will accelerate the commercial roll-out of Epi proColon(R) in North America
and mean a significant time and resource advantage for Epigenomics between
now and market launch of the product.

- End of Ad hoc -

Contact Epigenomics AG

Antje Zeise | CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386

ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.

---------------------------------------------------------------------------

Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------